MetLife Investment Management’s Accolade Inc ACCD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-42,958
| Closed | -$300K | – | 2953 |
|
|
2025
Q1 | $300K | Sell |
42,958
-379
| -0.9% | -$2.54K | ﹤0.01% | 1972 |
|
|
2024
Q4 | $148K | Buy |
43,337
+6,268
| +17% | +$22.3K | ﹤0.01% | 2453 |
|
|
2024
Q3 | $143K | Sell |
37,069
-6,253
| -14% | -$24.5K | ﹤0.01% | 2463 |
|
|
2024
Q2 | $155K | Buy |
43,322
+8,702
| +25% | +$65.9K | ﹤0.01% | 2394 |
|
|
2024
Q1 | $363K | Hold |
34,620
| – | – | ﹤0.01% | 1847 |
|
|
2023
Q4 | $416K | Hold |
34,620
| – | – | ﹤0.01% | 1803 |
|
|
2023
Q3 | $366K | Hold |
34,620
| – | – | ﹤0.01% | 1819 |
|
|
2023
Q2 | $466K | Hold |
34,620
| – | – | ﹤0.01% | 1739 |
|
|
2023
Q1 | $498K | Hold |
34,620
| – | – | ﹤0.01% | 1643 |
|
|
2022
Q4 | $270K | Hold |
34,620
| – | – | ﹤0.01% | 2058 |
|
|
2022
Q3 | $395K | Buy |
34,620
+5,826
| +20% | +$63.5K | ﹤0.01% | 1813 |
|
|
2022
Q2 | $213K | Hold |
28,794
| – | – | ﹤0.01% | 2273 |
|
|
2022
Q1 | $506K | Buy |
28,794
+10,627
| +58% | +$196K | ﹤0.01% | 1768 |
|
|
2021
Q4 | $479K | Hold |
18,167
| – | – | ﹤0.01% | 1528 |
|
|
2021
Q3 | $766K | Hold |
18,167
| – | – | 0.01% | 1270 |
|
|
2021
Q2 | $987K | Buy |
18,167
+5,811
| +47% | +$282K | 0.01% | 1167 |
|
|
2021
Q1 | $561K | Buy |
12,356
+7,057
| +133% | +$340K | 0.01% | 1457 |
|
|
2020
Q4 | $231K | Hold |
5,299
| – | – | ﹤0.01% | 1906 |
|
|
2020
Q3 | $206K | Buy |
+5,299
| New | +$183K | ﹤0.01% | 1853 |
|
Other funds holding ACCD
MetLife Investment Management's ACCD Position: Q2 2025 in Review
MetLife Investment Management sold out of Accolade Inc (ACCD) in Q2 2025, closing a stake of 42,958 shares — an estimated $300K sold.
MetLife Investment Management first reported a position in ACCD in Q3 2020 and held it in 19 quarters. The position peaked at $987K in Q2 2021. 1 fund tracked by Wall St. Rank holds ACCD as of Q2 2025.
- MetLife Investment Management reported no remaining Accolade Inc position as of Q2 2025 after selling out during the quarter.
- MetLife Investment Management sold 42,958 Accolade Inc shares in Q2 2025, an estimated $300K.
- MetLife Investment Management first reported a position in Accolade Inc in Q3 2020 and held it in 19 quarters.
- MetLife Investment Management's Accolade Inc position peaked at $987K in Q2 2021.
- 1 fund tracked by Wall St. Rank held Accolade Inc as of Q2 2025.
Based on MetLife Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.